Alzheimer's & Dementia Clinical Trial Tracker — Monitor the Neurodegenerative Pipeline

A rapidly evolving pipeline worth monitoring daily

The Alzheimer's therapeutic landscape is changing faster than at any point in recent history. With lecanemab and donanemab establishing proof of concept for amyloid removal, and a wave of second-generation programs, combination approaches, and tau-targeting therapies entering clinical development, the pipeline is adding new programs weekly.

For neuroscience-focused pharma teams, biotech investors, and patient advocacy organizations working in Alzheimer's, daily trial monitoring is no longer a nice-to-have — it's essential.

What to monitor in the Alzheimer's space

• Anti-amyloid monoclonal antibody Phase 2/3 programs (post-lecanemab era)
• Tau-targeting therapies: anti-tau antibodies, ASOs, small molecules
• Neuroinflammation programs: TREM2 agonists, microglial modulators
• Prevention trials in at-risk populations (APOE4 carriers, amyloid-positive cognitively normal)
• Combination therapies targeting multiple hallmarks simultaneously
• Biomarker-enriched trial designs using PET or CSF/plasma p-tau181
• Lewy body dementia, frontotemporal dementia, vascular dementia programs

Who uses Alzheimer's trial monitoring

Neuroscience-focused pharma and biotech

Companies in the Alzheimer's space track competitor program updates as part of routine competitive intelligence. New program registrations, Phase 2/3 transitions, and trial terminations all affect pipeline valuation and strategy.

Alzheimer's patient and caregiver advocacy groups

Organizations like the Alzheimer's Association, CurePSP, and disease-specific foundations help patients and families find clinical trial opportunities. Real-time awareness of recruiting trials is core to their mission.

Academic memory disorder centers

Neurologists at academic centers refer appropriate patients to trials. Knowing what's recruiting in early AD, MCI, or at-risk populations directly affects which patients get referred and when.